[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-345587-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-345587-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","serum-biomarkers-as-personalised-medicine-for-diagnostic-and-therapeutic-approaches-of-hepatocellular-carcinoma","Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma","","Hepatocellular carcinoma (HCC) poses a major public health challenge as incidence and mortality continue to rise. Early detection is difficult because symptoms are often nonspecific and traditional diagnostic methods have limited performance. This literature review evaluates three serum biomarkers—alpha-fetoprotein (AFP), des-γ-carboxyprothrombin (DCP), and glypican-3 (GPC3)—for personalised diagnostic and therapeutic strategies. Findings suggest AFP and DCP mainly support diagnosis, while GPC3 can inform both diagnosis and therapy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/serum-biomarkers-as-personalised-medicine-for-diagnostic-and-therapeutic-approaches-of-hepatocellular-carcinoma/345587/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/serum-biomarkers-as-personalised-medicine-for-diagnostic-and-therapeutic-approaches-of-hepatocellular-carcinoma/345587.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is early diagnosis of hepatocellular carcinoma challenging?","Question",{"text":63,"@type":64},"Early diagnosis is difficult due to nonspecific symptoms and limitations of traditional diagnostic approaches, which can also lead to false positives or negatives.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do AFP, DCP, and GPC3 differ in their roles for HCC?",{"text":68,"@type":64},"AFP and DCP are primarily used for diagnostics, while GPC3 serves both diagnostic and therapeutic purposes.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review say about limitations and practical challenges of these biomarkers?",{"text":72,"@type":64},"The review highlights issues such as limitations in sensitivity and specificity for early-stage detection and challenges including biopsy-related problems and funding constraints.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},345587,1790174183,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Taher et al. Journal of the Egyptian National Cancer Institute (2026) 38:7  \n[https://doi.org/10.1186/s43046-026-00342-1](https://doi.org/10.1186/s43046-026-00342-1)  \nJournal of the Egyptian National Cancer Institute  \nREVIEW Open Access  \nSerum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma  \nMuhammad Taher1*, Muhamad Aqil Ikram Muhamad Asri 1, Nur Damia Abdul Rahman 1, Nur Eleisha Zamzuri1, Nur Syazwani Mohammad Farizal1,2, Junaidi Khotib3, Deny Susanti2, Nurul Athirah Hasdan 1,  \nMuhammad Salahuddin Haris5 and Rita Rakhmawati4  \nAbstract  \nHepatocellular carcinoma (HCC) is a critical public health concern due to its rising incidence and mortality.  \nEarly diagnosis is challenging due to nonspecific symptoms and limitations of traditional methods. This study explores the potential of three key biomarkers, serum alpha-fetoprotein (AFP), des-γ-carboxyprothrombin (DCP), and glypican-3 (GPC3), in advancing personalized medicine for HCC, focusing on their roles in diagnostics and therapeutics. We conducted a literature review using specific keywords to narrow our search. Our findings indicate that AFP and DCP are primarily used for diagnostics, while GPC3 serves both diagnostic and therapeutic purposes. AFP is commonly used in late-stage detection due to its limited sensitivity and specificity in early stages, which can lead to false diagnoses. DCP plays a significant role as both a diagnostic tool and therapeutic target, while GPC3 is used to differentiate malignant from non-cancerous liver tissues. The review highlights the mechanisms, roles, and personalised treatments associated with these biomarkers, while also addressing challenges such as biopsy issues and funding limitations. In conclusion, the development and improvement of AFP, DCP, and GPC3 as biomarkers for the diagnostics and treatment of HCC are important. Thus, their limitations should be addressed as these biomarkers play a crucial role in modern cancer therapy and are critical for increasing the survival rates of HCC patients.  \nKeywords Hepatocellular carcinoma, Serum biomarkers, Diagnostic, Therapeutic, Alpha fetoprotein, Des-γ -carboxyprothrombin, Glypican-3  \n*Correspondence: Muhammad Taher[mtaher@iium.edu. my](mtaher@iium.edu. my)  \n1Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, Malaysia  \n2Department of Chemistry, Kulliyyah of Science, International Islamic University Malaysia, Kuantan, Pahang, Malaysia  \n3Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia 4Department of Pharmacy, Sebelas Maret University, Surakarta, Indonesia 5Department of Pharmacy, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Perak, Malaysia  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/.)[.](http://creativecommons.org/licenses/by/4.0/.)  \nTaher et al. Journal of the Egyptian National Cancer Institute (2026) 38:7 Page 2 of 11  \nIntroduction  \nThe steadily increasing incidence and mortality rates of liver cancer worldwide continue to position it as a critical public health c","cbCainT49oEA0Wwq","https://ap.wps.com/l/cbCainT49oEA0Wwq","pdf",1337298,11,"English","# Abstract\n# Keywords\n# Introduction","[{\"question\":\"Why is early diagnosis of hepatocellular carcinoma challenging?\",\"answer\":\"Early diagnosis is difficult due to nonspecific symptoms and limitations of traditional diagnostic approaches, which can also lead to false positives or negatives.\"},{\"question\":\"How do AFP, DCP, and GPC3 differ in their roles for HCC?\",\"answer\":\"AFP and DCP are primarily used for diagnostics, while GPC3 serves both diagnostic and therapeutic purposes.\"},{\"question\":\"What does the review say about limitations and practical challenges of these biomarkers?\",\"answer\":\"The review highlights issues such as limitations in sensitivity and specificity for early-stage detection and challenges including biopsy-related problems and funding constraints.\"}]","Serum biomarkers as personalised medicine for diagnostic and therapeutic approaches of hepatocellular carcinoma | PDF",1790058184,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c100ba6434f4ed6cea81a6ff95e845c1.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d0117ef91dd1bf928370a4682e8ded7.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/04ba345d77671135187b6acbf86d7e25.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8be4d56ef738121f1621e28e414ef6a6.webp",980,1306]